

MilliporeSigma Response to the COVID-19 Pandemic

At MilliporeSigma, we are helping to respond to the COVID-19 pandemic with products and solutions which empower scientists to detect and characterize viruses and to develop vaccines and therapies. As a global life science tools and equipment supplier, we are committed to providing the necessary research tools and reagents, diagnostic products and reagents, therapy manufacturing products and vaccine development products that can aid the global scientific effort to fight this novel virus. We have consolidated this product offering on a dedicated [COVID-19 webpage](#), providing a one-stop-shop of approximately 200 products and corresponding information for academic labs and biopharmaceutical companies working to combat the virus.

We continue to support many of our customers working on COVID-19 projects through our products and services, providing for more than 25 testing solutions (RT-PCR and serological diagnostics for both high-throughput centralized and distributed point-of-care settings), including eight of the top 10 IVD market leaders; more than 45 different vaccines, consisting of several platforms that include DNA, Inactivated, Live Attenuated Virus, Viral Vector, Protein Subunit and mRNA; more than 20 monoclonal antibody, plasma products and antivirals.

In addition, we are tapping into our existing collaborations to support projects that target COVID-19 vaccine and therapy development. Our collaboration with the Jenner Institute was instituted in 2017 to lay the foundation for large scale vaccine production; today, we support the process development and scale up of their COVID-19 vaccine candidate, ChAdOx1 nCoV-19, which is now in clinical trials. Our collaboration with Baylor College of Medicine began in 2018 to develop vaccines for neglected tropical diseases and today is still a work in progress but will likely support an early stage vaccine candidate using some of our process components and the process developed collaboratively.

As a company committed to solving tough problems and accelerating access to health, we are not only focused on end-product solutions during this extraordinary time. To provide this level of support for the critical measures now underway to contain and treat COVID-19 and to continue providing products that support the development and manufacturing of over-the-counter drugs to complex cell and gene therapies, we are working hard to ensure minimal disruption to our supply chain while remaining committed to the safety of our employees and customers. Our 59 manufacturing sites and 100+ distributions centers around the world remain operational to ensure that our biopharmaceutical customers have the products and services they need to serve the health needs of a global population.

Along with this, our top priority remains the safety and well-being of our employees. At each of our sites, we have arranged remote working whenever possible and are leveraging virtual meeting technology to continue collaborating with the global scientific community. For those employees who continue to develop, manufacture, package and ship products or provide services at our sites, we are implementing workplace distancing precautions, de-densification with staggered shifts and regimented cleaning schedules. Our leaders are working to keep our employees informed through a number of channels — from email to virtual town halls as well as a global network of hotlines — to answer employee questions in each country, address company policies, offer guidelines on working from home, and provide resources from WHO, CDC, local governments and our benefits providers.



To aid the ongoing scientific response to COVID-19, we continue to monitor the global situation closely, establishing protocols and guidelines to minimize the impact whenever possible to our sites and supply. We have mobilized a global task force to actively evaluate the overall supply chain of both our products and key raw materials suppliers to mitigate any potential disruption. Leveraging business continuity plans, we remain dedicated to serving our customers in all markets.

Throughout all of this, we are following guidance outlined by the WHO, CDC and governments of impacted countries, and our global sites have relevant and approved preparedness plans and are empowered to act per their local scenarios, as necessary.

For more information, contact:

Rachel Bloom-Baglin

Communications and Executive Communications, MilliporeSigma

978 436-1725 | rachel.bloom-baglin@milliporesigma.com

